References
- 1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361(19):1872-1885.
- 2. Vardiman JW, Harris NL, Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100(7):2292-302.
- 3. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25(23): 3503-10.
- 4. Greenberg P1, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088
- 5. Greenberg PL1, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65
- 6. A Pardanani, A Tefferi. Cytogenetic risk stratification in myelodisplastic syndromes: Are we there yetJ J Clin ONcol 2012;30:2703-270410.1200/JCO.2012.42.5033
- 7. Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. Loss of the Y Chromosome An Age-Related or Clonal Phenomenon in Acute Myelogenous Leukemia/Myelodysplastic Syndrome? Arch Pathol Lab Med 2008;132:1329-32
- 8. Fenaux P, Mufti GJ, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol 2009;10:223–32.
- 9. Plaseski T, Noveski P, Trivodalieva S, Efremov GD, Plaseska-Karanfilska D.. Quantitative fluorescent-PCR detection of sex chromosome aneuploidies and AZF deletions/duplications. Genet Test. 2008;12(4):595-605.
- 10. Noveski P, Madjunkova S, Sukarova-Stefanovska E, Matevska Geshkovska N, Kuzmanovska M, Dimovski A, Plaseska-Karanfilska D. Loss of Y chromosome in peripheral blood of colorectal and prostate cancer patients. PLoS One. 2016;11(1):e0146264
- 11. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1): 9–16.
- 12. Itzykson R1, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411
- 13. Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108(2):419-25